Helicobacter pylori eradication is recognized as the initial therapy for gastric low-grade, B-cell, mucosa-associated lymphoid tissue (MALT) lymphoma. This study assesses (i) the H. pylori eradication rates for various fi rst-and second-line and rescue therapies and (ii) the associated reinfection rates in patients .
INTRODUCTION
Th e stomach is the most frequent site of primary extranodal non-Hodgkin ' s lymphomas, accounting for more than 75 % of gastrointestinal tract lymphomas (1) . It is widely accepted that Helicobacter pylori infection is the main pathogenic factor for the development of gastric low-grade, B-cell, mucosa-associated lymphoid tissue (MALT) lymphoma (2 -4) . Undeniably, bacterial eradication is well recognized as the initial therapy for earlystage neoplasia (5, 6) . Some observations would suggest that H. pylori has an important role even in high-grade-transformed MALT lymphoma, referred to as diff use large B-cell lymphoma with features of MALT (DLBCL-MALT) according to the World Health Organization classifi cation (7) . Indeed, several observations have reported a total regression of such a lymphoma aft er bacterial eradication when an early-stage neoplasia was diagnosed (8) .
Although primary gastric lymphoma remains a rare disease, its frequency has been increasing in recent decades (2, 9) . Similarly, the prevalence of H. pylori resistance toward diff erent antibiotics is increasing worldwide, reducing the effi cacy of standard eradication therapies (10) . Th erefore, the management of H. pylori infection in patients with lymphoma remains Eradication Therapy for Helicobacter pylori in Patients With Gastric MALT Lymphoma: A Pooled Data Analysis a challenge for the future, particularly for gastroenterologists, hematologists, and oncologists.
Series reporting the effi cacy of H. pylori eradication therapies in these patients are generally small, and diff erent therapeutic regimens have been used. Consequently, it is diffi cult to understand how diff erent eradication therapies are eff ective in curing the infection in MALT lymphoma patients. H. pylori infection recurrence, due to either reinfection (i.e., infection with a new bacterial strain) or recrudescence (reappearance of the same strain aft er a bacterial clearance due to therapy), is a rather infrequent event following eff ective therapies, being quoted < 2 % yearly despite the high prevalence of the infection in the general population (11) . However, it has been reported that infection recurrence in gastric lymphoma patients may cause disease relapse (3) . Th erefore, bacterial reinfection is a relevant issue for the management of these patients.
We carried out a systematic review of the literature aimed at assessing (i) the H. pylori eradication rate aft er diff erent fi rst-, second-line, and rescue therapies and (ii) the reinfection rate in these patients.
METHODS

Literature search
Separate computer-assisted searches were performed using the PUBMED. Each search was performed on all English language articles through June 2008, using the exploded medical subject heading terms " lymphoma, " " Helicobacter pylori, " " therapy, " and " eradication. " Boolean operators (NOT, AND, OR) were also used in succession to narrow and widen the search. Only studies regarding MALT lymphoma or DLBCL-MALT lymphoma of the stomach were considered. Th e full paper of all relevant studies was retrieved, and manual searches of reference lists from identifi ed relevant papers were performed to identify any additional studies that may have been missed using the above-mentioned procedure. When more than one publication of the same investigator group was available, only the most updated version, including the entire sample size, was considered for this pooled data analysis. For those relevant studies not describing either the eradication regimen used or the eradication rate following diff erent regimens, we attempted to contact the authors. Studies regarding pediatric series, those published only in abstract form, single case reports, or short reports, including less than three patients treated with the same therapy, reviews, and those studies published in a language other than English, were not taken into account.
Data extraction
Two investigators (A.Z. and C.H.) extracted data from studies meeting the selection criteria. Data were extracted regarding (i) the number of patients treated with H. pylori eradication therapy; (ii) the drug regimen used for fi rst-, second-line, or further rescue therapies; (iii) the number of patients in whom the infection was eradicated successfully (either provided directly or calculated); and (iv) the number of patients with bacterial reinfection at follow-up. H. pylori reinfection was defi ned as the reappearance of bacteria у 12 months aft er a verifi ed eradication, whereas the recrudescence of infection < 12 months was considered as a therapy failure (12, 13) . Th ere was a strong agreement between the two investigators in data extraction, and a fi nal accord was achieved for the three trials with discordant data interpretation.
Statistical analysis
H. pylori eradication rates and their 95 % confi dence intervals were calculated for each treatment regimen used. Data comparison between diff erent therapies was performed using either the 2 -test or Fisher ' s exact test, as appropriate. A P value < 0.05 was considered statistically signifi cant.
RESULTS
Search results
Aft er a thorough review of the titles, abstracts, and manuscripts of the potentially relevant studies, the full paper of the 77 studies regarding H. pylori eradication in gastric lymphoma patients was retrieved and evaluated carefully. Of these, 34 studies with 39 therapeutic arms met the inclusion criteria for this pooled analysis (14 -47) , whereas 43 studies were not included. Th e exclusion criteria were (i) manuscripts reporting preliminary data comprehensively provided elsewhere (22 studies); (ii) lack of information on the therapy regimen used or the eradication rate was not computable (18 studies); and (iii) only eradicated patients were included in a long-term follow-up study (3 studies).
Descriptive analysis
Among the 34 studies included in this pooled data analysis, 29 were concerned with MALT lymphoma patients (14 -42) , 2 with DLBCL-MALT (43, 44) , and 3 with both lymphoma groups (45 -47) . Data regarding 1,271 treated patients were available, including those of 1,215 patients with MALT lymphoma and 56 patients with DLBCL-MALT. Th e median sample size was 21 patients, ranging from 3 to 120 patients in diff erent series. A total of 19 studies with 747 patients were obtained from Asia, 14 studies with 496 patients from Europe, and only 1 study with 28 from the United States. Th e study design was prospective in 26 trials and retrospective in the remaining 8 series.
H. pylori eradication
As a fi rst-line treatment, a standard triple therapy with a proton pump inhibitor plus two antibiotics (a combination of two of the following: amoxycillin, clarithromycin, metronidazole / tinidazole), all b.i.d. (twice daily), was the most frequently used regimen that was administered for 7 -28 days. A highdose dual therapy, including omeprazole 40 mg t.i.d. (thrice daily) and amoxycillin 750 mg t.i.d. for 14 days was the second preferred therapy, whereas a quadruple therapy, including proton pump inhibitor (b.i.d.) and bismuth salts (four times daily) plus two antibiotics (a combination of two of the following:
clarithromycin, tetracycline, metronidazole) administered three or four times daily for 21 days, was used in a single study (22) . Th e infection was cured overall in 1,156 of 1,271 patients (91 % ; 95 % confi dence interval (95 % CI) = 89.4 − 92.5), with an eradication rate ranging from 50 to 100 % in diff erent series (median 93.8 % ). As shown in Table 1 , the eradication rate was higher aft er dual therapy as compared with the 7-or 14-day triple therapies, although the diff erence failed to reach statistical signifi cance ( P = 0.0525). No statistically signifi cant diff erence in the cure rate was observed among the 7-, 14-day triple therapies and quadruple regimen. Diff erent cure rates were achieved in diverse geographic areas, being 690 of 747 (92. Data on second-line therapy were available in 19 studies with 20 therapeutic arms (15,17,20,22,23,25 -29,31,33,35,37,38,41, 45,47) , including 99 of 115 unsuccessfully treated patients with a previous therapy. A 14-day, high-dose dual therapy, a 7 -14 day standard triple therapy, a 7 -21 day quadruple therapy, or a culture-based therapy was used for re-treatment in 94 cases, whereas the regimen used was not specifi ed for the remaining 5 patients. Th e infection was cured overall in 88 of 99 patients (80.8 % ; 95 % CI = 82.7 − 95.1), with an eradication rate ranging from 58.3 to 100 % in diff erent series (median 100 % ). As shown in Table 2 , a signifi cantly higher eradication rate was achieved aft er triple therapy compared with the quadruple regimen, whereas no signifi cant diff erence emerged among the other regimens. Data on further therapies (from three to fi ve attempts) were available for 8 of 11 patients who failed to respond to the second-line therapy, and bacterial eradication was achieved in 6 (75 % ) cases. By considering all the available data, H. pylori infection was ultimately cured in 1,250 patients, accounting for eradication rates of 98.3 % (95 % CI = 97.6 − 99) and 99.8 % (95 % CI = 99.6 − 100) at intention-to-treat and per-protocol analysis levels, respectively. No study reported data on primary H. pylori antibiotic resistance before therapy. Moreover, although in two studies (15, 29) rescue therapies were based on antibiotic susceptibility results, no specifi c data have been provided.
Aft er H. pylori therapy, gastric lymphoma regression was achieved in 973 (77.8 % ) of 1,250 successfully cured patients, with a remission rate ranging from 50 to 100 % in diff erent studies. In detail, the remission rate was signifi cantly higher in Asian (81.8 % ; 95 % CI = 79 − 84.6) compared with that in Western (71.9 % ; 95 % CI = 68 − 75.8) patients (81.8 vs. 71.9 % ; P = 0.0002). Moreover, neoplasia regression occurred more frequently in MALT lymphoma (78.5 % ; 95 % CI = 76.2 − 80.8) patients than in DLBCL-MALT (62 % ; 95 % CI = 48.5 − 75.4) patients (78.5 vs. 62 % ; P = 0.0062). Dual vs. either 7-or 14-day triple therapies: P = 0.0525; 7-vs. 14-day triple therapies: P = 0.9; quadruple therapy vs. either 7-or 14-day triple therapies: P = 0.5. (14,15,17,18,20,21,23, 24,25 -27,28,33,34,37,39,41,42,45,47) . However, data of two studies were excluded because of the timing from bacterial eradication and recurrence had been not provided (33, 37) . Th ese series enrolled 676 patients, with a follow-up ranging from 2 to 134 months. Overall, 18 (2.7 % ; 95 % CI = 1.4 − 3.9) bacterial reinfections were observed during 1,828 patientyears of follow-up, giving a yearly reinfection rate of 0.7 % . In detail, the reinfection ranged from 0, as observed in 8 studies with 286 patients, to 1 − 22.2 % as found in 10 trials with 390 patients. As shown in Table 3 , the reinfection was observed in 14 (77.8 % ) patients at 12 − 24 months, whereas it occurred at 26, 55, 80, and 113 months aft er bacterial eradication in the remaining 4 (22.2 % ) cases.
Compliance and side effects
Surprisingly, no study reported data on compliance with the H. pylori eradication therapies. Similarly, the incidence of side eff ects as well as the number of patients who eventually interrupted treatment earlier were not given in any study.
DISCUSSION
Primary gastric MALT lymphoma is neoplasia for which a relationship with H. pylori infection is widely recognized (1 -6) . Current European (48) , US (49) , Japanese (50) , and Italian guidelines (51) strongly suggest bacterial eradication in all MALT lymphoma patients. Indeed, a review of 24 studies comprising 780 patients found that complete lymphoma regression aft er H. pylori eradication is achieved in 35 -100 % of patients, depending on the disease stage (3) . Disappointingly, curing H. pylori infection is become quite diffi cult in clinical practice because of to the increased prevalence of bacterial resistance against diff erent antibiotics, particularly toward clarithromycin and metronidazole (10, 52) . Consequently, eradicating the infection in lymphoma patients could be a challenge in the future. Th e present pooled data analysis assessed the success rate of diff erent therapies for H. pylori eradication in MALT lymphoma patients. Th e fi rst relevant fi nding was that fi rst-line therapies are highly eff ective in these patients, achieving an overall cure rate >90 % . In detail, a 14-day, very high-dose (omeprazole 120 mg / day) dual therapy seems to be the best therapeutic approach, achieving the highest eradication rate. However, such a therapy regimen has been used only in Germany and Austria, in 3 studies with a total of 126 patients (17, 31, 43) . Th erefore, this fi nding may not be generalizable to other countries and deserves to be confi rmed in further trials. Similarly, a high eradication rate was achieved aft er a quadruple regimen, but it was administered to 28 patients only (22) . Moreover, the therapy duration (21 days) is probably a major limitation of such a treatment in clinical practice. We found that the most frequently used fi rst-line therapy in lymphoma patients was the 14-day triple therapy, followed by the 7-day standard regimen. It is noted that, our data failed to fi nd a diff erence in the effi cacy between these therapy schedules, the cure rates being 90.3 and 90.1 % , respectively. Th erefore, the use of the longer triple therapy regimen seems to be unjustifi ed, the cost being twice as much as that of the 1-week schedule. Th e success achieved by triple therapies in lymphoma patients would appear to be higher than that observed following similar regimens in the general population, where 78 and 73 % eradication rates following 14-and 7-day regimens, respectively, were calculated in a recent meta-analysis (53) . Although it is quite diffi cult to interpret such an observation, a higher compliance with the therapy is foreseeable in patients with a neoplastic disease as compared with those with benign disease, such as non-ulcer dyspepsia. On the other hand, a role for the disease could also be hypothesized, similar to duodenal ulcer, for which the bacterial strains involved and their distribution in the stomach seem to favor eradication (54) . Although the high-dose dual therapy seems to be highly eff ective even as second-line therapy, only a very few cases have been treated (8 patients), whereas triple therapies (7 -14 days) (39 patients) and quadruple regimen (37 patients) were the most used treatments. Th e comparison found a significantly higher cure rate following the triple regimens compared with the more complicated quadruple therapy. By contrast, the effi cacy of a culture-based approach does not seem to be so impressive, besides being largely impracticable in clinical practice.
H. pylori reinfection in the general population is quite a rare event, with a yearly rate as low as 1.97 % being estimated (11) . Th e present pooled data evaluated data regarding nearly 700 patients followed-up until 10 years, and a yearly reinfection rate of 0.7 % was observed. Although H. pylori reinfection was observed even many years aft er eradication, bacterial recurrence occurred within 2 years in the majority of patients, as described in the general population (11) . Th is fi nding would suggest that the possibility of reinfection is progressively decreasing at longterm follow-up. Th is is an interesting observation for patient management, the infection recurrence being a risk factor for lymphoma relapse (3, 6) .
In conclusion, this is the fi rst comprehensive ( ~ 1,300 patients) analysis of the therapeutic management of H. pylori in gastric lymphoma patients. Data found that this infection seems to be easily managed in these patients, being ultimately cured in nearly all the cases.
